Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Global characterization of proteome and lysine methylome features in EZH2 wild-type and mutant lymphoma cell lines.
|
31846764 |
2020 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Enhancer of zeste homolog 2 (EZH2), an H3K27-specific histone methyltransferase, has been shown to be frequently overexpressed in various human cancers including lymphoma.
|
30218753 |
2019 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
2019; published online January 28, https://doi.org/10.1038/s41588-018-0338-y) examined the effects of mutant EZH2 on the 3D architecture of the lymphoma genome, highlighting the potential relevance of chromatin folding dynamics.
|
30885427 |
2019 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overexpression and gain-of-function mutations in EZH2 are regarded as oncogenic drivers in lymphoma and other malignancies due to the silencing of tumor suppressors and differentiation genes.
|
31419226 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we present the rationale, key pre-clinical and early clinical findings of small molecule EZH2 inhibitors for use in lymphoma as well as future challenges and potential opportunities for combination therapies.
|
29473431 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we critically review the emerging role of EZH2 in malignancies, the development of small molecule inhibitors of EZH2, and their application in lymphoma.
|
30112706 |
2018 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.
|
28811957 |
2017 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The antitumor efficacy of pharmacological EZH2 inhibition depends on SESTRIN1, indicating that mTORC1 control is a critical function of EZH2 in lymphoma.
|
28659443 |
2017 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that Ezh2(Y641F) induces lymphoma and melanoma through a vast reorganization of chromatin structure, inducing both repression and activation of polycomb-regulated loci.
|
27135738 |
2016 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results demonstrated that ZLD10A, as a novel EZH2 inhibitor, could be a potential promising agent for the treatment of EZH2 mutant lymphoma.
|
27261606 |
2016 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific binding by the BCL6 transcriptional repressor and the presence of a non-canonical PRC1-BCOR-CBX8 complex.
|
27505670 |
2016 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Importantly, the EZH2(Y641) mutants recurrently implicated in lymphoma pathogenesis are unable to bind β-TrCP.
|
24469040 |
2015 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We discovered that YC-1 induces apoptosis and inhibits tumour growth of breast cancer cells via down-regulation of EZH2 by activating c-Cbl and ERK.
|
24697523 |
2014 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We observed a dramatic acceleration of lymphoma development in this combination model of Myc and EZH2(Y641F).
|
24802772 |
2014 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
New therapeutic approaches targeting aberrant H3K27 methylation include small molecules that block the action of mutant EZH2 in germinal center-derived lymphoma.
|
24987060 |
2014 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These genomic data suggest that targeting the EZH2 MT activity is a valid therapeutic strategy for the treatment of lymphoma patients with EZH2 mutations.
|
25457180 |
2014 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The reduction of CSC self-renewal via EZH2 inhibition offers a potentially attractive therapeutic approach to counter the aberrant activation found in lymphoma and leukemia.
|
24097338 |
2014 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, our study uncovers an oncogenic role of EZH2 independent of its methyltransferase activity in NKTL and suggests that targeting EZH2 may have therapeutic usefulness in this lymphoma.
|
23529930 |
2013 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations associated with disease progression such as isocitrate dehydrogenase (IDH) 1, IDH2, EZH2, serine/arginine-rich splicing factor 2 (SRSF2), p53, casitas B-lineage lymphoma (c-CBL), ikaros zinc fingers (IKZF), neurofibromin 1 (NF1) and runt-related transcription factor 1 (RUNX1) are described.
|
23298878 |
2013 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Herein, we identify mutation of EZH2 A677 to a glycine (A677G) among lymphoma cell lines and primary tumor specimens.
|
22323599 |
2012 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EZH2 mediated transcriptional repression through its methyltransferase activity at the chromatin level has certain influence on lymphoma, and there might exist a therapeutic window for the development of new agents and identification of novel diagnostic markers based on EZH2.
|
23075734 |
2012 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined inhibition of HDAC3 and EZH2 cooperatively disrupted the MYC-EZH2-miR-29 axis, resulting in restoration of miR-29 expression, downregulation of miR-29-targeted genes, and lymphoma growth suppression in vitro and in vivo.
|
23079660 |
2012 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These EZH2 mutations may drive the proliferation of lymphoma and make EZH2 a molecular target for patients harboring these mutations.
|
22850114 |
2012 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
|
23051747 |
2012 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This represents the first example of a disease-associated gain-of-function mutation in a histone methyltransferase, whereby somatic EZH2 Y641 mutations in lymphoma act dominantly to increase, rather than decrease, histone methylation.
|
21190999 |
2011 |